Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com
Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com
StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report published on Saturday morning. The brokerage issued a sell rating on the biotechnology company's stock.
斯托克新聞網在週六上午發佈的一份報告中開始報道貝勒羅芬治療公司(納斯達克：BLPH-GET Rating)的股票。該經紀公司對這家生物技術公司的股票發佈了賣出評級。
Other analysts have also issued research reports about the company. Brookline Capital Acquisition decreased their price target on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th. Brookline Capital Management decreased their price target on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th.
其他分析師也發佈了關於該公司的研究報告。Brookline Capital Acquisition在4月4日星期一的一份研究報告中將他們對貝勒羅芬治療公司的目標價從26.00美元下調至19.00美元。Brookline資本管理公司在4月4日星期一的一份研究報告中將他們對貝勒羅芬治療公司的目標價從26.00美元下調至19.00美元。
Bellerophon Therapeutics Stock Performance
貝勒羅芬治療公司股票表現
BLPH opened at $1.28 on Friday. Bellerophon Therapeutics has a 1 year low of $0.67 and a 1 year high of $4.98. The stock's 50 day simple moving average is $1.05 and its 200-day simple moving average is $1.83.
BLPH上週五開盤報1.28美元。貝勒羅芬治療公司的一年低點為0.67美元，一年高位為4.98美元。該股的50日簡單移動均線切入位為1.05美元，200日簡單移動均線切入位為1.83美元。
About Bellerophon Therapeutics
關於貝勒羅芬治療公司
(Get Rating)
(獲取評級)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
貝勒羅芬治療公司是一家臨牀階段治療公司，專注於在美國開發治療心肺疾病的產品。其產品包括INOPulse，這是一種用於治療肺動脈高壓的專有脈衝式一氧化氮輸送平臺。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- MarketBeat: Week in Review 7/11 – 7/15
- Should You Have These Two Banks In Your Portfolio?
- Is Coupang's Stock On The Verge Of A Turnaround?
- Why Shopify Stock Split...And is as Shoppable as Ever
- Verint Systems Stock is a Customer Engagement Play
- 免費獲取StockNews.com關於貝勒羅芬治療(BLPH)的研究報告
- MarketBeat：回顧一週7/11-7/15
- 你的投資組合中應該有這兩家銀行嗎？
- Coupang的股票即將翻身嗎？
- 為什麼Shopify股票拆分...並一如既往地適合購物
- Verint Systems Stock是一場客户互動活動
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受貝勒羅芬治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bellerophon治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。